David G. Brauer

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Eric Hans Jensen · 2 shared papers, 2026 · strength 0.59
   • Paper Trajectories of health care contact days experienced by decedents who underwent curative-intent surgery for pancreatic … DOI 10.1093/oncolo/oyag150↗
   • Paper Age-Based Left-Digit Bias in the Treatment of Pancreatic Adenocarcinoma. DOI 10.1007/s12029-026-01459-1↗
2. Christopher James LaRocca · 2 shared papers, 2026 · strength 0.59
   • Paper Trajectories of health care contact days experienced by decedents who underwent curative-intent surgery for pancreatic … DOI 10.1093/oncolo/oyag150↗
   • Paper Age-Based Left-Digit Bias in the Treatment of Pancreatic Adenocarcinoma. DOI 10.1007/s12029-026-01459-1↗
3. Julia A. Harrison · 1 shared paper, 2025 · strength 0.54
   • Paper Updates in the Surgical Management of Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.gtc.2024.07.003↗
4. Vishal R. Patel · 1 shared paper, 2026 · strength 0.30
   • Paper Trajectories of health care contact days experienced by decedents who underwent curative-intent surgery for pancreatic … DOI 10.1093/oncolo/oyag150↗
5. Arjun Gupta · 1 shared paper, 2026 · strength 0.30
   • Paper Trajectories of health care contact days experienced by decedents who underwent curative-intent surgery for pancreatic … DOI 10.1093/oncolo/oyag150↗
6. Whitney Victoria Johnson · 1 shared paper, 2026 · strength 0.30
   • Paper Trajectories of health care contact days experienced by decedents who underwent curative-intent surgery for pancreatic … DOI 10.1093/oncolo/oyag150↗
7. Jacob S. Ankeny · 1 shared paper, 2026 · strength 0.29
   • Paper Age-Based Left-Digit Bias in the Treatment of Pancreatic Adenocarcinoma. DOI 10.1007/s12029-026-01459-1↗
8. Qianyun Luo · 1 shared paper, 2026 · strength 0.29
   • Paper Age-Based Left-Digit Bias in the Treatment of Pancreatic Adenocarcinoma. DOI 10.1007/s12029-026-01459-1↗
9. Schelomo Marmor · 1 shared paper, 2026 · strength 0.29
   • Paper Age-Based Left-Digit Bias in the Treatment of Pancreatic Adenocarcinoma. DOI 10.1007/s12029-026-01459-1↗
10. Julia Button · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
11. Erin M. Dickey · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
12. Caitlin A. Hester · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
13. Michael E. Lidsky · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
14. Brian E. Diskin · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
15. Elishama N. Kanu · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
16. Ethan S. Agritelley · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
17. Emil Lou · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
18. Nipun B. Merchant · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
19. Daniel P. Nussbaum · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
20. Brett Logan Ecker · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
21. Susanna Varkey Ulahannan · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗
22. Jashodeep Datta · 1 shared paper, 2025 · strength 0.19
    • Paper SMAD4 Alterations are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment o… DOI 10.1097/sla.0000000000006966↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.